Avanir Pharmaceuticals

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit http://www.avanir.com. Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide. Avanir® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.
Type
Subsidiary
Parent Company
Otsuka Pharmaceutical
HQ
Aliso Viejo, US
Founded
1988
Website
avanir.com
Avanir Pharmaceuticals was founded in 1988 and is headquartered in Aliso Viejo, US

Avanir Pharmaceuticals Office Locations

Avanir Pharmaceuticals has offices in Aliso Viejo, New York,
Aliso Viejo, US (HQ)
400 30 Enterprise

Avanir Pharmaceuticals Metrics

Avanir Pharmaceuticals Summary

Founding Date

1988

Total Funding

$30 m

Investors

Avanir Pharmaceuticals is a subsidiary of Otsuka Pharmaceutical

Avanir Pharmaceuticals Financial Metrics

FY, 2013FY, 2014

Cash

$55.3 m$271.9 m

Accounts Receivable

$12.5 m$22.8 m

Inventories

Current Assets

$71.8 m$300.8 m

PP&E

$1.6 m$3.6 m

Total Assets

$76.1 m$307 m

Accounts Payable

$5.9 m$6.7 m

Current Liabilities

$34.8 m$32.1 m

Additional Paid-in Capital

$519 m$824.3 m

Retained Earnings

($500.5 m)($551 m)

Total Equity

$18.5 m$273.4 m

Financial Leverage

4.1 x1.1 x
FY, 2013FY, 2014

Net Income

($75.5 m)($50.4 m)

Depreciation and Amortization

$826.5 k$1.4 m

Accounts Receivable

($5.5 m)($10 m)

Inventories

Accounts Payable

$2.9 m$372 k

Cash From Operating Activities

($65.4 m)($48.7 m)

Purchases of PP&E

($448.3 k)($3.1 m)

Cash From Investing Activities

($361.6 k)($3.4 m)

Interest Paid

$2.7 m$4.3 m

Income Taxes Paid

$3.2 k$3 k

Avanir Pharmaceuticals Company Life

You may also be interested in